Eunice S. Wang, MD, Daniel Pollyea, MD, MS, and Naval Daver, MD
In this segment, “What’s Next for AML?”, Eunice S. Wang, MD, Daniel Pollyea, MD, MS and Naval Daver, MD give us a snapshot. In AML, roles for minimal residual disease (MRD) remain unsettled and controversial. However, progress is now being made on better defining MRD and potential intervention. Currently, many novel agents are being studied for AML, including diverse targeted therapies and immunotherapies (e.g., antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies). Novel combinations in upfront and relapsed settings are also emerging. Given the high level of research activity in AML, treatment paradigms will continue to evolve in the coming years.